Archive · 7 Sep 2026
Novartis India Buys Minipress Brands for ₹1,250 Crore
Novartis India is buying the Indian trademarks for two medicines called Minipress and Minipres.
The deal is worth ₹1,250 crore and includes some related intellectual property.
One medicine, Minipress XL, contains a drug called prazosin.
It is mainly used for high blood pressure and some urinary problems caused by an enlarged prostate.
Minipress XL generated ₹228.6 crore in revenue in the data cited by Novartis India.
Pfizer will stop making and selling the medicine in India.
Its sales will end on September 7, 2026.
Dr Reddy’s Laboratories will keep commercialising certain covered brands until September 30, 2026.
Novartis India acquired Pfizer’s Minipress and Minipres trademarks in India for ₹1,250 crore.
The transaction includes certain intellectual property rights linked to the two brands.
Minipress XL, containing prazosin, generated ₹228.6 crore in revenue, according to July 2026 IQVIA data.
Pfizer will stop marketing, distributing and selling Minipress XL in India from September 7, 2026.
Dr Reddy’s Laboratories will continue commercialising certain covered brands until September 30, 2026.
- Who
- Novartis India, Pfizer Inc, Pfizer Products Inc, Pfizer Ltd and Dr Reddy’s Laboratories.
- What
- Novartis India acquired the Minipress and Minipres trademarks and related intellectual property rights in India, while Pfizer is discontinuing Minipress XL sales.
- When
- The transaction was approved and completed simultaneously; Pfizer’s sales will end on September 7, 2026, and Dr Reddy’s commercialisation arrangement continues until September 30, 2026.
- Where
- India, with the transaction involving Mumbai-based operations mentioned in the reports.
- Why
- Pfizer Inc decided to discontinue manufacturing Minipress XL, leading Pfizer to exit the product in India and Novartis India to acquire the Indian brand rights.
- Acquisition value
- ₹1,250 crore
- Acquired brands
- Minipress and Minipres
- Medicine uses
- Minipress XL contains prazosin and is primarily used for hypertension and urinary symptoms associated with benign prostatic hyperplasia.
- Minipress XL revenue
- ₹228.6 crore, according to IQVIA MAT July 2026 data cited by Novartis India.
- Pfizer sales end
- September 7, 2026
- Pfizer Ltd payment
- Pfizer Ltd will receive a lump-sum payment of US$13.9 million, approximately ₹131.38 crore, from its US-based parent in connection with the discontinuation.
- Dr Reddy’s continuation
- Dr Reddy’s Laboratories will continue commercialising covered brands until September 30, 2026.
